Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary Endpoint Reported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis IND

SAN DIEGO , Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced topline data from its ATLAS trial, a Phase 2b randomized,

  Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy study   Both patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring rescue therapy   Patients demonstrated rapid and sustained mJDA score